Home › Non-Small Cell Lung Cancer › NCT07339254

Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

Experiences With and Attitudes Towards Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer (NSCLC) - A Single Center, Survey-Based Study

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* \* Age ≥ 18 years.
* \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
* \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
* \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.

Exclusion Criteria:

* \* Patients is unable to consent for themselves
* \* Patient has not yet completed the 1st cycle of ICI-based therapy

About the study

This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.

What is being tested

• Non-Interventional Study (other)

Sponsor: University of Southern California · Participants: 40 · Started: Mar 12, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07339254

Locations in the U.S.

Conditions

• Non-Small Cell Lung Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.